133737-48-1

Basic information

• Product Name: Pagoclone
• Synonyms: PAGOCLONE;1H-Isoindol-1-one, 2-(7-chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-(5-methyl-2-oxohexyl)-;2-(7-Chloro-2-naphthyridin-1,8-yl)-3-(5-methyl-2-oxohexyl)isoindolin-1-one;Pagoclone Labeled d4
• CAS NO: 133737-48-1
• Molecular Formula: C₂₃H₂₂ClN₃O₂
• Molecular Weight: 407.89268
• Mol File: 133737-48-1.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: Pagoclone(CAS DataBase Reference)
• NIST Chemistry Reference: Pagoclone(133737-48-1)
• EPA Substance Registry System: Pagoclone(133737-48-1)

Safety Data

• Hazardous Substances Data: 133737-48-1(Hazardous Substances Data)

Usage

Description

Pagoclone is a new cyclopyrrolone partial agonist. In animal models of antianxiety activity, pagoclone is more potent than benzodiazepines, is less sedating, and has a high therapeutic index (Table 29–1). In clinical studies, pagoclone is well tolerated and does not appear to cause sedation or affect psychomotor or cognitive performance. In studies of volunteers, it has been shown that it does not cause withdrawal symptoms on abrupt discontinuation after 14 days. These factors all suggest that pagoclone may be an important drug for the future. It is currently entering dose-ranging and comparative studies involving patients with anxiety disorders, and in a pilot crossover study, it reduced panic attacks; adverse effects were not different from or more numerous than those reported with placebo (Sandford et al. 1998).

Uses

Different sources of media describe the Uses of 133737-48-1 differently. You can refer to the following data:
1. Anti-anxiety agent.
2. Pagoclone is a partial GABAA agonist, used to reduce panic attacks and appear to decrease symptoms of generalized anxiety.

Side effects

Pagoclone is a novel cyclopyrrolone that acts as a partial GABAA receptor agonist. Preclinical studies suggest that pagoclone may have clinical utility as an anxiolytic agent, as well as a reduced incidence of side-effects. Pagoclone differs from benzodiazepines in that it does not emit a full electrophysiological response to GABA stimulation in vitro. Adverse events appear to be dose-related, with the most common side-effects reported as somnolence, dizziness, headache, asthenia, and lethargy, though cognitive effects have not yet been tested.

Upstream product

• 136604-91-6 [(5-methyl-2-oxo)hexyl]triphenylphosphonium bromide 
• 42809-49-4 6-methyl-1-hepten-3-one 
• 100-52-7 benzaldehyde 
• 55243-02-2 2,7-dichloro-1,8-naphthyridine 
• 15944-33-9 2-chloro-7-amino-1,8-naphthyridine 
• 33779-03-2 2-(2-methoxycarbonylethyl)benzoic acid 
• 3849-22-7 (3-oxo-2,3-dihydro-1H-isoindol-1-yl)-acetic acid 
• 55112-41-9 2-hydroxy-7-N-phthalimidyl-1,8-naphthyridine 
• 632620-24-7 2-amino-7-hydroxy-1,8-naphthyridine sulfate 
• 134664-69-0 isoamylcarbonylmethylenetriphenyl phosphorane 
• 55112-38-4 2-(7-chloro-1,8-naphthyridin-2-yl)-3-hydroxy-isoindolin-1-one 
• 141-86-6 2.6-diaminopyridine 
• 110-12-3 5-Methyl-2-hexanone 
• 147031-30-9 (±)-2-[1-(7-chloro-1,8-naphthyridin-2-ylamino)-6-methyl-3-oxoheptyl]benzoic acid 

Downstream Products

• 147031-30-9 (±)-2-[1-(7-chloro-1,8-naphthyridin-2-ylamino)-6-methyl-3-oxoheptyl]benzoic acid 

Relevant articles and documents

Preparation method of anti-anxiety drug pagoclone or pazinaclone

The invention discloses a method for catalytically synthesizing an anti-anxiety drug pagoclone or pazinaclone and analogues thereof by utilizing Rh(III). The method comprises the following steps: reacting benzaldehyde and 2-aminopyridine compounds in a solvent in the presence of a rhodium catalyst and acetate, and producing an effective guide group in situ; and reacting the guide group and substituted olefin under rhodium catalysis, and performing after-treatment after the reaction is completed, thereby obtaining a compound having a nitrogen heterocyclic framework. According to the preparationmethod, two independent reactions (amide formation and carbon-hydrogen activation) are catalyzed by using rhodium, and a synthetic strategy of self-assembling high-efficiency guide groups is successfully realized. The reaction is carried out based on simple raw materials, an isoindoxone skeleton having substitution characteristics is synthesized in a simple and mild catalytic system by utilizinga 'one-pot process', the operation is simple and convenient, the reaction conditions are mild, the yield is high, and atom economy is high.

Cu/Fe Catalyzed Intermolecular Oxidative Amination of Benzylic C-H Bonds

We report a Cu/Fe co-catalyzed Ritter-type C-H activation/amination reaction that allows efficient and selective intermolecular functionalization of benzylic C-H bonds. This new reaction is featured by simple reaction conditions, readily available reagents and general substrate scope, allowing facile synthesis of biologically interesting nitrogen containing heterocycles. The Cu and Fe salts were found to play distinct roles in this cooperative catalysis. With a little help: A Ritter-type intermolecular amination of benzylic C-H bonds with acetonitrile, co-catalyzed by CuII/FeIII is reported. A wide array of biologically interesting nitrogen containing heterocycles was prepared from 2-alkyl benzoic acids and heteroaromatic carboxylic acids under operationally simple conditions. The Cu and Fe salts were found to play distinct roles in this cooperative catalysis.

Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone

The present invention relates to methods for making racemic 2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxohexyl)-1-isoindolinone and (+)-2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone.